Dec 21, 2020

TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference

Dec 13, 2020

TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors

Dec 11, 2020

TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors

Nov 12, 2020

TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 10, 2020

TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity

Sep 29, 2020

TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

Sep 08, 2020

TCR² Therapeutics to Participate in Two Upcoming Conferences in September

Aug 12, 2020

TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 06, 2020

TCR² Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

Jul 28, 2020

TCR² Therapeutics Announces Pricing of Public Offering of Common Stock